[
    {
        "type": "text",
        "text": "SCIENTIFIC REPORTS ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "OPEN ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Received:30 April 2015   \nAccepted:30 November 2015   \nPublished: 06 January 2016 ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Chengyan Dong1,2,\\*, Sujuan Yang1,\\*, Jiyun Shi², Huiyun Zhaol1,3, Lijun Zhong³, Zhaofei Liu1, Bing Jia1& Fan Wang1,2,4 ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "We describe herein dual-modalityimaging ofintraperitoneal colon tumor using an avidin/biotin pretargeting system.A novel dual-modality probe, 99mTc-HYNIC-lys(Cy5.5) $\\cdot P E G _ { 4 }$ -biotin, was designed,synthesized and characterized.Single-photon emision computed tomography/computed tomography (SPECT/CT)imaging and near infrared fluorescence(NIRF)imaging were developed using intraperitoneal LS180 human colon adenocarcinoma xenografts.Following avidin preinjection for 4hours, $\\mathsf { 9 9 m } _ { \\mathsf { T c - H Y N I C - l y s } ( \\mathsf { C y } 5 . 5 ) \\cdot \\mathsf { P E G } _ { 4 } }$ -biotin could successfully detect colon tumors of different sizes inside the abdominal region using both modalities,and the imaging results showed no differences. Biodistribution studies demonstrated that the tumors had a very high uptake ofthe probe 99mTcHYNIC-lys(Cy5.5) $\\cdot P E G _ { 4 }$ -biotin $( 1 2 . 7 4 \\pm 1 . 8 9 \\% \\mathsf { I D } / \\mathsf { \\Omega }$ gat 2h p.i.),and the clearance from blood and other normal tissues occured very fast.The low tumor uptake in the non-pretargeted mice $( \\pm . 6 3 \\pm$ $0 . 5 0 \\%$ ID/g at2h p.i.) and tumor cellstaining results showed excellent tumor binding specificity of the pretargeting system.The ability of the novel probe to show excellent imaging quality with high tumor-to-background contrast,a high degree of binding specificity with tumors and excellent in vivo biodistribution pharmacokinetics should prove thatthe avidin/biotin based dual-modality pretargeting probe is a promising imaging tool during the entire period of tumor diagnosis and treatment. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Surgerycombined withchemotherapyis regardedas the most efective treatment for cancer patients1.Toadequately discriminate between tumorand normal tisues and determine the tumor-free marginare the key demands of oncologic surgery for asurgeon2.With intraoperative, tumor-specific detection supplied by imaging modalities, surgeons insurgerycould localize the tumor lesion specifically,lading to more radical excision oftumor tissue that could effectively protect the function of adjacent normal tissues and ofer an improved prognosis.Image-guided surgery using appropriate probes could assist surgeons by providing real-time feedback with visual observation and palpation3.Among the imaging modalities investigated to date,optical imaging,particularly near-infrared fluorescence (NIRF; 700- to $9 0 0 \\mathrm { - n m }$ wavelength) imaging,is clearly perfectly suited for image-guided surgery due to its superior resolutionand sensitivity, relativelylow tissue absorption and scatering,as wellas minimal autofluorescence of NIR light in this spectrum4.Many preclinical and clinical studies have demonstrated the potential use of NIRF imaging in image-guided surgery. Recently, Gooitzen Mreported the first-in-human use of intraoperative tumor-specific fluorescence imaging for real-time surgicalvisualization of tumor tissue in patients with ovarian cancerl. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "However,the limited tissue penetrationof NIRF imaging leads tolow detection in intraperitoneal tumors before surgery.Single-photon emissioncomputed tomography (SPECT)with its high penetration abilityand sensitivity has been used routinely for clinicalapplications in the early detection oflesions,staging malignant tumors,and the evaluation of therapeutic effcacy5.In the present study,we developedasimultaneous optical and nuclearcontrast ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1Medical lsotopes Research Center and Department of Radiation Medicine,School of Basic Medical Sciences, Peking University,Beijing10ol91,China.²InterdisciplinaryLaboratory,nstituteofBiophysics,ChineseAcademyof Sciences,Beijing100101,China.3Medicaland HealthyAnalyticalCenter,Peking University,Beijing100191,China. 4State Key Laboratoryof Naturaland Biomimetic Drugs,CenterforMolecularandTranslational Medicine,Peking University,Beijing0ol91,China.\\*Theseauthorscontributedequallytothiswork.Correspondenceandrequestsfor materials should be addressed to B.J.(email: jiabing@bjmu.edu.cn) ",
        "page_idx": 0
    },
    {
        "type": "image",
        "img_path": "images/5329b0fadc35c7b5e24a6f4b1b09cd339e4543ed5e075887975e1cc96b827ad3.jpg",
        "img_caption": [
            "Figure 1. Synthesis of HYNIC-lys $( \\mathbf { C y 5 . 5 } )$ $\\mathbf { \\cdot P E G _ { 4 } }$ -biotin.Reagents and conditions: (a) EDC,Sulfo-NHS, DMI $\\mathrm { \\vec { \\cdot } { H _ { 2 } O } } ( 1 { : } 1 )$ $2 8 ^ { \\circ } \\mathrm { C } ,$ （2号 $1 0 \\mathrm { h }$ $5 2 . 1 \\%$ (b) $20 \\%$ piperidine, DMF, rt, $0 . 5 \\mathrm { h }$ $8 2 . 9 \\%$ (c) $\\mathrm { H } _ { 2 } \\mathrm { O } { : } \\mathrm { D M F } = 1 { : } 1$ ,DIPEA,pH 8.5, $2 8 ^ { \\circ } \\mathrm { C }$ 0 $1 0 \\mathrm { h }$ 0 $5 8 . 2 \\%$ ; (d) $5 \\%$ Hydrazine,DMF,rt, $0 . 5 \\mathrm { h }$ $8 7 . 0 \\%$ ; (e) 0.1M $\\mathrm { N a } _ { 2 } \\mathrm { B } _ { 4 } \\mathrm { O } _ { 7 } ;$ （204号 $\\mathrm { p H } 8 . 5$ ,dark,r.t, $1 0 \\mathrm { h }$ $5 2 . 1 \\%$ "
        ],
        "img_footnote": [],
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "agent,the dual-function SPECT/NIRF probe,which could beused for detecting tumor effectively during the entire period of the diagnosis and therapy,even in image-guided surgery. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "To improve the application potential ofthe novel probe,we designed a two-step pretargeting approach using a biotin/avidin interaction system,resulting in enhanced tumor-to-nontumor ratiosand modest signalamplification atthetumor sitedue tothe tetramericarchitecture ofavidin forbiotin6.Pretargeting supports an optimal targeting process,which first localizes the tumor tissue using anunlabeled bispecific molecule before administering asmall fast-clearing signal compound.The combination of high specific uptake in tumors and low retention in normal tissues that the pretargeting system brings could affct the image-guide surgery, which relies on the maximized contrast between the tumor and non-tumor tissues7.Moreover,we embed the tetra (ethylene glycol) $\\mathrm { ( P E G _ { 4 } ) }$ spacer between the biotin motif and signal motif to improve the pharmacokinetics in vivo8. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Results ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Synthesis of HYNIC-lysine(Cy5.5)- $\\mathsf { P E G } _ { 4 }$ -biotin.To make the probe bi-functional, protected lysine was applied in this synthesis. $\\mathrm { H Y N I C \\mathrm { - } l y s ( C y } 5 . 5 ) \\mathrm { - } \\mathrm { P E G } _ { 4 } .$ -biotin was prepared in five steps (Fig.1),with an overall yield of $1 1 . 4 \\%$ ,starting from PEG modified biotin, $\\mathbf { R } { - } \\mathbf { N } \\mathbf { H } _ { 2 }$ $\\mathbf { R } \\mathbf { - N } \\mathbf { H } _ { 2 }$ was coupled with Dde and Fmoc protected lysine (1),and subsequently deprotected in $20 \\%$ piperidine in DMF to yield 2.The introduction of the chelator HYNIC group used for $^ { 9 9 \\mathrm { m } } \\mathrm { \\ddot { T } c }$ labeling was accomplished by coupling with s-SBZ-HYNIC, followed by deprotection of the Dde groups with $5 \\%$ hydrazine in DMF The optical $\\mathrm { C y } 5 . 5$ region (4) was linked to the remaining N-terminal region of compound 3,and the final product compound 5 was prepared.In all of the synthetic steps, the compounds were purified and characterized by reversed-phase preparative HPLC. Allof the new conjugates were analyzed by both HPLC and mass spectrometry to confirm the identity of the products (See Methods and Supplementary Figures). The HPLC purity of the final product was ${ > } 9 5 \\%$ before being used for $^ { 9 9 \\mathrm { m r } } \\mathrm { T c }$ -labeling. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Radiochemistry. $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ -HYNIC-lys $( \\mathrm { C y } 5 . 5 )$ $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin was prepared using a non-stannous formulation with tricine and TPPTS because TPPTS is a reducing agent for $\\mathrm { { N a } [ ^ { 9 9 m } \\mathrm { { T c O _ { 4 } } ] } }$ . After radiolabeling,the radiochemical purity of the $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ -labeled probe was ${ > } 9 8 \\%$ as measured by radio-HPLC.The solution stability of $\\mathrm { \\ ^ { 9 9 m } T c - H Y N I C - l y s ( C y 5 . 5 ) - P E G _ { 4 } }$ biotin wasstudied byradio-HPLC insalineand inthe presenceof excesscysteine （204号 $\\mathrm { ( 1 . 0 \\mathrm { m g / m L } }$ $\\mathrm { p H } = 7 . 4 ,$ ,and the radiotracer was stable in the saline and cysteine solution for ${ > } 6 \\mathrm { h }$ ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Dual-modality imaging.We tested the application of the probe in the LS180 colon tumor model. Nude mice were intraperitoneally injected with $1 \\times 1 0 ^ { 6 }$ of cultured LS18O cells.It takes 10 days to obtain colon tumors of the appropriate size in the animal model (Fig.2A,C).Based on the pretargeting strategy,the tumor-bearing animals were pretreated with avidin ( $\\mathrm { 1 5 \\mu \\mathrm { g / g } }$ whole body weight) for $\\mathrm { 4 h }$ prior to the radiolabeled probe injection, followed by administration of $1 0 0 \\mu \\mathrm { L }$ of the labeled conjugate 5 $( 1 8 . 5 \\bar { \\mathrm { M B q } } ) ^ { 9 }$ . The imaging of the colon tumor model was carried out after $2 \\mathrm { h }$ of radiotracer injection using two imaging modalities. SPECT/CT and image analysis were performed usinga rodent scanner (NanoSPECT/CT; Mediso Ltd.).As shown inFig.2B,tumors inthe stomach,intestine,spleenand pancreas were clearly visualized(white arrow),and the activitylevel inthe abdominal region except the kidneys and bladder(particularly liver and intestine) was very low.In addition, some smal-sized tumors could be distinguished very clearly (Fig.2C-E).The high tumor uptakeand superior tumor-to-background ratios make it possible for tumor detection in the diagnosis before surgery and lesion recheck in treatment evaluation after surgery. ",
        "page_idx": 1
    },
    {
        "type": "image",
        "img_path": "images/422750b54b0f36edf1da900fc3a635d58fbcad10ab16157122041c1cb5ea8f2f.jpg",
        "img_caption": [
            "Figure 2. SPECT/CT imaging of 99mTc-HYNIC-lys(Cy5.5)- $\\mathbf { \\cdot P E G _ { 4 } }$ -biotin in nude mice bearing LS180 colon tumor. (A,B) Dashed arrows mark location ofLS180 tumors oflarge size among the liver, stomach,spleen and pancreas.(C.D,E) The solid arrows mark the location of LS180 tumors of smal size along the intestine wall. "
        ],
        "img_footnote": [],
        "page_idx": 2
    },
    {
        "type": "image",
        "img_path": "images/849816cdea0075e1b3e995026682aa4738d842cddbc03541f7ecc1a35a5ecb9d.jpg",
        "img_caption": [
            "Pre-T:AvidinPretargeted NPT:NoAvidinPretargeted ",
            "Figure 3. NIR-fluorescence imaging of 99mTc-HYNIC-lys(Cy5.5)- $\\mathbf { \\cdot P E G _ { 4 } }$ -biotin in nude mice bearing LS180 colon tumors.(A) Tissue uptake of HYNIC-lys $( \\mathrm { C y } 5 . 5 )$ 车 $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin.Yellow arrows mark tumors.(B,C)Local NIRF imaging of mouse intestines with colon tumors.Dashed arrows mark tumors. (D,E) Contrast betwen tumoruptakes ofHYNIC-lys(Cy5.5)- $\\cdot \\mathrm { P E G } _ { 4 }$ -biotinwith and without pretargeted avidin.Solid line arrows mark the tumors.(F,G) HE staining of selected tumor section. "
        ],
        "img_footnote": [],
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "Figure 3A displays NIRF imaging of all ofthe major organs with the dual-modality probe using Maestro2 (PerkinElmer).The tumorsof differentsizes couldbewellobserved duetothehigh tumoruptake,andthe uptake of normaltissues in theabdominalregion exceptthe kidneys was relativelylow.Asshown inFig.3B,C,fourcolon tumors were co-localized very wellbetween the photographand NIRFimage.To test the effectivenessof the pretargeting system,LS180 colon tumor-bearing nude mice were injected with the same dose of99mTc-HYNIC-lys(- $\\mathrm { C y } 5 . 5 )$ 1 $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin and vehicle saline instead of avidin pretargeting.The contrast results were shown in Fig.3D,E. The tumor uptake ofthe pretargeting group was significantly higher than that ofthe non-pretargeting group,indicating that endogenic avidin exists ataverylowconcentration innormaltissues and affects the imagingquality very negligibly.The hematoxylinand eosin (H&E) staining of selected tissue sections identifiedthe high biotin-based probe uptake region consistent with the tumor region.The results are shown inFig.3F,G.Figure 3 demonstrates thetumorlocation and margin status inthe colon tumor model.The tumors grown along the intestine wallcould be easily detected by NIRF imaging because of the high tumor-to-intestine ratio. ",
        "page_idx": 2
    },
    {
        "type": "image",
        "img_path": "images/d6377f97024949cc326b3ae57c3840a655d12284eef6e3a38600fd0bbc5c0240.jpg",
        "img_caption": [
            "Figure 4. Biodistribution of 99mTc-HYNIC-lys $( \\mathbf { C } \\mathbf { y } 5 . 5 )$ $\\mathbf { \\cdot P E G } _ { 4 }$ -biotin in nude mice bearing LS180 colon tumors.(A) Biodistribution of the probe at 1h, $2 \\mathrm { h }$ and $\\mathrm { 4 h }$ p.i.(B) Biodistribution of the probe with or without pretargeted avidin. "
        ],
        "img_footnote": [],
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "Biodistribution Characteristics. The nude mice bearing LS180 xenografts were used to evaluate the biodistribution characteristics and excretion kinetics of 99mTc-HYNIC-lys(Cy5.5)- $\\mathrm { P E G } _ { 4 }$ -biotin. In general, ${ } ^ { 9 9 \\mathrm { m } } \\mathrm { T c } \\mathrm { - } \\mathrm { H Y N I C - } \\mathrm { l y s } ( \\mathrm { C y } 5 . 5 ) \\mathrm { - } \\mathrm { P E G _ { 4 } }$ -biotin showeda promising distribution in the tumor-bearing model(Fig.4).The radiolabeled probe displayed arapid clearance predominantly via the renal route as evidencedby higher kidney uptake and a rapid blood washout $( 1 . 1 4 \\pm 0 . 1 3 \\% \\mathrm { { I D / g } }$ and $0 . 3 2 \\pm 0 . 0 9 \\% \\mathrm { I D / g }$ at l and $^ { 4 \\mathrm { h } }$ p.i.,respectively). The intestines and other disscted tissues except the kidneys showed verylow uptake,a finding that was also consistent with the imaging results.The LS180 tumor uptake was as high as $9 . 7 6 \\pm 2 . 9 9 \\% \\mathrm { I D / g }$ at $1 \\mathrm { h }$ p.i., then increased to $1 2 . 7 4 \\pm 1 . 8 9 \\% \\mathrm { { I D / g } }$ at $2 \\mathrm { h }$ p.i. ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "To test the tumor-targeting specificity ofavidin,the biodistributionof non-pretargeted mice was performed with the results shown in Fig.4B.The tumor uptake at $2 \\mathrm { h }$ p.i. was $1 . 6 3 \\pm 0 . 5 0 \\% \\mathrm { I D } { } / \\mathrm { g }$ without avidin pretargeting, indicating tat the specific targeting ofavidin inLS180 tumors and endogenic avidindid not afect the tumor uptake. The uptakes of other normal tissues did not change in both groups,further demonstrating the tumor-targeting specificity of avidin. ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "Cell Staining.We utilized $e x$ -vivo microscopy to visualize the location of avidin in LS180 cels. Cells were incubated for 2hours at $3 7 ^ { \\circ } \\mathrm { C }$ with avidin followed by incubation with HYNIC-lys(Cy5.5)- $\\cdot \\mathrm { P E G } _ { 4 }$ -biotinat room temperature (RT) for1h.Nuclei were labeled with DAPI for $5 \\mathrm { { m i n } }$ at RT.Immunofluorescence staining showed that the avidin could bind to the tumor cels and most ofthe avidin accumulated in the nuclear region (Fig. 5). ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "Discussion ",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "We reported the synthesis and characterizationofanovel pretargeting dual-labeled imaging probe that contains an NIR dye (Cy5.5) for fluorescence opticalimaging and a nuclide ${ \\binom { 9 9 \\mathrm { m } } { \\mathrm { T c } } }$ for nuclear imaging. Lysine was used to link these two motifs to the avidin-targeting molecule biotin (Fig.1).Furthermore,we embedded a $\\mathrm { P E G } _ { 4 }$ spacer between the biotin motif and signal motifs to improve the pharmacokinetics in vivo and reduce steric hindrance of biotin/avidin binding.Toachieveabetterimaging result,we firstcombined thetwo concepts of“dual-modality imaging\"and“pretargeting\". ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "The pretargeting concept was proposed by Reardan et al.1° as an alternative to coupling achelate directly to antibodies in 1985.This promising concept quicklyled to the development ofradioimmunotherapy (RIT),overcoming ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "Avidin Pretargeted ",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "No Avidin Pretargeted ",
        "page_idx": 4
    },
    {
        "type": "image",
        "img_path": "images/bbb971c300f67376d443ae5ef50305c278beefb018e661d55cf45520c99c79a8.jpg",
        "img_caption": [
            "Figure 5.Fluorescent staining of LS180 cells with HYNIC-lys(Cy5.5). $\\mathbf { \\cdot P E G _ { 4 } }$ -biotin (red) and DAPI (blue). \\* means HYNIC-lys $\\mathrm { ( } \\mathrm { Y } 5 . 5 )$ 1 $\\mathrm { P E G } _ { 4 }$ -biotin. "
        ],
        "img_footnote": [],
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "thelimitation oftheslow bloodclearance of directly radiolabeled tumor-targeted antibodies.Pretargeting involves two steps inwhichthe pretargetingagents localizeinthe tumorfirst,andthentheradiolabeledcompounds bindto the pretargeting agents,12.Theuptakeof the normal tisues,particularlytheliver,coulddecline aftertheclearance. Preclinical studies have already shown that tumor detection of the pretargeting probes with many radionuclides (18F, 124I, $^ { 6 4 } \\mathrm { C u }$ and $^ { 6 8 } \\mathrm { G a }$ for PET imaging; 9mTc, 131I,and $^ { 1 1 1 } \\mathrm { { I n } }$ for SPECT imaging) is effectively more excellent than detection using directly radiolabeled peptide probes or even directly radiolabeled antibodies13-18. ",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "In our study,biotin-avidin binding-based method was used for two reasons: their very high affinity $( 1 0 ^ { - 1 5 } \\mathrm { { M } ) }$ and superior signalamplification with four binding sites forbiotin per avidin.This biotin/avidin pretargeting system has ben proven tobe a successful approach to tumor imaging and radioimmunotherapy by many preclinical and clinical studies.Avidin is alsoa tumor-targeted moleculel9 that has also beenreported to bindto glycoprotein-binding receptors (lectins)on cancer cells and facilitate internalization into cancer cells.The presence of endogenous lectins with galactoside-binding specificities has been reported in various tumor cels,and their expression leads toahigher metastatic potential.Moreover,the high glycosylationand high pIofavidin may increase their binding properties20.Figure5clearly demonstrates thatavidin couldbind toLS180cellsspecificallyandlocalize in the cell nuclei region.Interestingly, we noticed a distinctive morphological feature- -morular structures—in the nuclei because nuclear biotin inclusions named biotin-rich opticalyclear nuclei(BROCN)are demonstrated in certain tumors,includinglow-grade adenocarcinomaofthefetallung type (L-FLAC)/well-differentiated fetaladenocarcinoma (WDFA),cribriform-morular variant of papillrythyroid carcinoma (CMV),adenomaof the galbladder, adenoma ofthecolon,pancreatoblastoma,endometrioidtumoroftheovary,andadenoacanthomaoftheuterus21. ",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "The avidin/biotin pretargeting system could successfully detect tumors in both imaging modalities (Figs 2 and 3).The tumor model was established via the intraperitoneal injection of cultured LS180 human colon adenocarcinoma cells.Two types of tumors could be observed in the abdominal region.Larger tumors grewin the stomach,pancreas and spleen (Fig.2A,dashed white arrow),and smaller tumors were shown along the intestine wall(Fig.2C,solid white arrows).Figure 2 illustrates the SPECT/CT imaging of the new probe $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ -HYNIC-lys(- $\\mathrm { C y } 5 . 5 )$ $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin in LS180 tumor-bearing nude mice.The tumors of diferent sizes could be clearly seen in the images (Fig.2B for the larger size; Fig.2D,E for the smaller sizes).The pretargeted $^ { 9 9 \\mathrm { m r } } \\mathrm { T c }$ radiotracer only accumulates in the kidneyand tumorlesion,even in the smallones.Combined with the biodistribution shown in Fig. 4, ${ } ^ { 9 9 \\mathrm { m } } \\mathrm { T c } \\mathrm { - } \\mathrm { H Y N I C - } \\mathrm { l y s } ( \\mathrm { C y } 5 . 5 ) \\mathrm { - } \\mathrm { P E G } _ { 4 }$ biotin is accumulated in tumors rapidly $( 9 . 7 6 \\pm 2 . 9 9 \\% \\mathrm { { I D / g } }$ t $\\boldsymbol { 1 \\mathrm { h } }$ p.i.) and cleared from the blood and other normal tissues very quickly $( 1 . 1 4 \\pm 0 . 1 3 \\% \\mathrm { { I D / g } }$ in blood, $4 . 0 4 \\pm 1 . 0 9 \\% \\mathrm { I D / g }$ in liver,and $2 . 4 2 \\pm 0 . 1 1 \\% \\mathrm { I D / g }$ in spleen at $ { 1 \\mathrm { h } }$ p.i.).The tumor achieves a maximum uptake at $^ { 2 \\mathrm { h } }$ p.i. $( 1 2 . 7 4 \\pm 1 . 8 9 \\% \\mathrm { { I D / g } ) }$ ： Tumor/blood ratios of $8 . 2 3 \\pm 2 . 2 1$ at 1h p.i. to as high as $1 8 . 9 8 \\pm 4 . 3 8$ at $2 \\mathrm { h }$ p.i. were obtained to support excellent tumor imaging. A high tumor/tissue ratio within $2 \\mathrm { h }$ is very beneficial for clinical imaging purposes because manyradionuclides with short half-lives could be used to reduce the radiation damage to the normal tissues of the patients (Supplementary Table 1). $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ is an important radionuclide for widespread imaging applications with ideal nuclear properties,including a short half-life $( t _ { I / 2 } = 6 \\mathrm { h }$ ),rich and diverse coordinationchemistry,high specific activity (single photon emission at $1 4 0 \\mathrm { k e V } .$ ),and easy availability at low cost from a commercial generator.In our study, the radiolabeling process was very easy,and the labeling yield was as high as $9 8 \\%$ . Tricine and the reducing agent TPPTS areused as thecoligands,and stannous chloride is not needed.It is notcomplicated to develop a kit formulation for routine preparation of the radiotracer. ",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "There is no single ideal modality for all experimental purposes223.Each modalityhas its ownadvantages and disadvantages.Nuclear imaging ofers good sensitivity at deep tissue sites and could detect orthotopic tumors and their metastatic lesions24.Additionally,optical imaging offers real-time and high-resolution imaging of fluorophores intumors25.For image-guidedsurgery,NIRF-based imaging is preferredbecauseof the relativelylowtissue absorption and minimal autofluorescence of NIR light.In this study, we developed an ex vivo optical imaging instead ofan in vivo imaging.Figure 3A shows the accumulation of the fluorescence in major organs.An optical image was overlaid ona white-light image for easy identification.At $2 \\mathrm { h }$ p.i.,the fluorescence signal intensities were mainlyatributable to the kidneys and tumors.Tumors of different sizes could be clearly distinguished (yellow solidarrows).The optical imaging data are consistent with nuclear imaging data.In clinic,SPECT/CTimaging can supplythe situationabout the tumorbefore thesurgery,including the size,locationand metastasis in the distant organs.With the accurate information, the surgery willbe guided with NIRFimaging fora more radicalexcision. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "Local NIRF imaging of mouse intestines with colon tumors showed more promising results (Fig.3B,C).All four tumors in the field could be imaged very clearly (white dashed arrows).HE staining of selected sections was performed to prove that the fluorescence probe accumulated in the tumor region (Fig. 3F,G).To investigate the specificity of avidin to LS180 tumor, we tested the contrast for the tumor uptake of HYNIC-lys(Cy5.5). $\\mathrm { . P E G _ { 4 } ^ { \\mathrm { ^ { - } } } }$ -biotin with and without pretargeted avidin (Fig.3D,E). Without avidin pretargeting,the tumor uptake was similar to thatofthe background,significantlylower than the pretargeted tumor uptake.Figure 4B demonstrated thatthe tumor uptake of the pretargeting group at $2 \\mathrm { h }$ p.i. $( 1 \\bar { 2 } . 7 4 \\pm \\mathrm { 1 . 8 9 \\% I D / g } )$ was significantly higher than that of the non-pretargeting group $( 1 . 6 3 \\pm 0 . 5 0 \\% \\mathrm { { I D / g } ) }$ . Additionally, there was no significant change in the probe uptake for the two groups in other organs like the heart, intestines, kidneys,lungs,liver and spleen. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "The avidin/biotin pretargeting dual-modality system successfully accomplished the purpose of the probe being able to efectively diagnose the tumorbefore the operation, guide the surgery and evaluate the treatment effect. Although researchonavidin targeted diseases is notsufficient,the exciting results ilustrate thatthis systemcould translate to other peptides and antibodies.By conjugating other targeting molecules with avidin,many receptors on thetumors and other diseases could be localized with the pretargeting molecules,then the receptors could be imaged with the dual-modality probe ${ } ^ { 9 9 \\mathrm { m } } \\mathrm { T c } \\mathrm { - } \\mathrm { H Y N I C - } \\mathrm { l y s } ( \\mathrm { C y } 5 . 5 ) \\mathrm { - } \\mathrm { P E G } _ { 4 }$ -biotin, which has many superior advantages suchas highbindingaffinity,highspecificity,high tumor/non-tumorratiosandfastclearancefromnormal tissues.The results could be identicalto those with SPECTimaging and NIRF imaging,supporting the accuracy ofthe detection.We willtestthis systemonother receptors to investigate the effectiveness.Basedon the expected favorable pharmacokinetic properties,we anticipate that the probe could beapplied clinicaly.However,the doses and imaging time should be determined before translation into the clinic.Moreover,the radiation exposure to surgeons and hospital staffmay limit the useof the probe in clinic.Although many studies have showed the radiation exposure to the operating team is only a minor problem for 99mTc-labelled tracers under formal SPECT imaging guided operating procedures26,27,the accurate absorbed staffdoses at operations should be measured where patients had received a preoperative injection of $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ -HYNIC-lys(Cy5.5) $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin to guarantee the safety of the surgical staff. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "In summary, we described the design,synthesis,and characterization of 99mTc-HYNIC-lys(Cy5.5)- $\\mathrm { . P E G _ { 4 } }$ -biotin, a novel dual-modality probe containing a HYNIC group for labeling the isotope $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ for SPECT imaging, and a $\\mathrm { C y } 5 . 5$ group for NIR fluorescence imaging. This is the first study on the combination of pretargeting and dual-modality imaging. Both modalities successfullydetectthecolon tumors of different sizes inside the abdominalregion.High tumoruptake,highbinding afinity,high specificityand loworganaccumulation make the probe a promising imaging tool.Employing both nuclear and optical imaging withthe pretargeting system may facilitate translation into clinical applications. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "Methods ",
        "text_level": 1,
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "Materials and Instruments. Chemicals purchased from commercial sources were of analytical grade or better and were used without further purification.Biotin- $\\cdot \\mathrm { P E G } _ { 4 }$ -amine(biotin) was obtained from BioMatrik (Jiaxing,China).Fmoc-Ne-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-lysine (lysine(-Dde)-Fmoc) was obtained from Ala biochem company (Jiangsu,China).1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC)and trifluoroacetic(TFA)were obtained from Fluka (Switzerland).N-Hydroxylsuccinimide (NHS),N,N-dimethylformamide (DMF),and diethylamine were obtained from Sigma (USA). Acetonitrile was obtained from Bardik &Jackson.Sodium sucinimidyl6-(2-(2-sulfonatobenzaldehyde)hydrazono)nicotinate (HYNIC-NHS) was a gift from Shuang Liu (Purdue University). $\\mathrm { N a ^ { 9 9 m } T c O _ { 4 } }$ was obtained from a commercial $^ { 9 9 } \\mathrm { M o } / { } ^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ generator (Beijing Atom High Tech Co., Ltd., China). ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "Allexperimental protocol were approved byPeking University Health Science Center Academic Commitee, including radiolabeling,in vivo imaging,and biodistribution studies.Allmethods were carriedout inaccordance with the approved guidelines. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "HPLC methods.All synthetic reactions were monitored by high-performance liquid chromatography (HPLC).The reversed-phase HPLC system was the same as that previously reported.Reversed-phase HPLC chromatography was performed on an YMC C-18 column ( ${ 5 \\mu \\mathrm { m } }$ $2 5 0 \\times 4 . 5 \\mathrm { m m }$ ）using a gradient solvent system at a flow rate of $1 \\mathrm { m L } / \\mathrm { m i n }$ .A gradient of acetonitrilel $\\phantom { + } 0 . 0 5 \\%$ trifluoroacetic(TFA) (phase A) and $\\mathrm { H } _ { 2 } \\mathrm { O } / 0 . 0 5 \\%$ TFA (phase B)was used. ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "HPLC method 1: Starting with $2 0 \\%$ acetonitrile/ $0 . 0 5 \\%$ TFA(phase A),the initial solvent mixture was held for $8 \\mathrm { { m i n } }$ ,followed by a gradient mobile phase from $2 0 \\%$ A at $8 \\mathrm { { m i n } }$ to $8 0 \\%$ A at $3 5 \\mathrm { { m i n } }$ and to $1 0 0 \\%$ at $4 0 \\mathrm { { m i n } }$ .HPLC method 2: Starting with $5 \\%$ acetonitrile $/ 0 . 0 5 \\%$ TFA(phase A),the initial solvent mixture was held for $8 \\mathrm { { m i n } }$ followed by a gradient mobile phase from $5 \\%$ A at $8 \\mathrm { { m i n } }$ to $8 0 \\%$ A at $3 5 \\mathrm { m i n }$ and to $1 0 0 \\%$ at $4 0 \\mathrm { { m i n } }$ .HPLC method 3: The mobile phase starting from $0 \\%$ A at $0 \\mathrm { m i n }$ to $8 0 \\%$ A at $3 5 \\mathrm { { m i n } }$ and to $1 0 0 \\%$ at $4 0 \\mathrm { m i n }$ .HPLC method 4: Starting with $5 \\%$ acetonitriler $0 . 0 \\dot { 5 } \\%$ TFA (phase A),the initial solvent mixture was held for $8 \\mathrm { { m i n } }$ ,followed bya gradient mobile phase from $5 \\%$ Aat $8 \\mathrm { { m i n } }$ to $4 7 . 2 \\%$ Aat $2 5 \\mathrm { m i n }$ and to $1 0 0 \\%$ at $3 0 \\mathrm { m i n }$ .HPLC method 5: Starting with $0 \\%$ （20 acetonitrile $\\phantom { 0 } { 1 0 . 0 5 \\% }$ TFA(phaseA),followed bya gradient mobile phase from $0 \\%$ Aat $0 \\mathrm { m i n }$ to $5 \\%$ Aat $5 \\mathrm { { m i n } }$ and to $6 6 \\%$ at $3 0 \\mathrm { m i n }$ ",
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Synthesis of Fmoc-lys(Dde)- $P E G _ { 4 }$ -biotin.Lysine(Dde)-Fmoc(12.92 mg; $2 4 . 2 \\mu \\mathrm { m o l }$ dissolved in $5 0 \\mu \\mathrm { L }$ of DMF),EDC( $\\cdot 1 5 . 6 4 \\mathrm { m g }$ dissolved in $5 0 \\mu \\mathrm { L }$ of $\\mathrm { H } _ { 2 } \\mathrm { O }$ ),andNHS ${ \\cdot } 9 . 5 2 \\mathrm { m g }$ dissolved in $5 0 \\mu \\mathrm { L }$ of DMF) were added to $\\mathrm { P E G } _ { 4 }$ -biotin (6.8 mg; $1 6 . 2 \\mu \\mathrm { m o l }$ dissolved in $5 0 \\mu \\mathrm { L }$ of DMF) at room temperature (RT).After stirring for $1 2 \\mathrm { h }$ at RT, the product was purified byHPLC (method 1).Fractions at $2 8 \\mathrm { m i n }$ were collected.Fmoc-lys(Dde)- $\\cdot \\mathrm { P E G } _ { 4 }$ -biotinwas obtained with a $5 2 \\%$ yield and ${ > } 9 5 \\%$ HPLC purity.The matrix-assisted laser desorption/ionization time-of-light mass spectrometry data were as follows: $\\mathrm { m } / \\mathrm { z } = 9 3 3 . 5 0$ for $[ \\mathrm { M } \\mathrm { + H } ] ^ { + }$ ,955.52 for $[ \\mathrm { M } \\mathrm { + N a } ] ^ { + }$ ,and 971.56 for $[ \\mathrm { M } { + } \\dot { \\mathrm { K } } ] ^ { + }$ $\\mathrm { ( C _ { 4 9 } H _ { 6 8 } N _ { 6 } O _ { 1 0 } S ; }$ calculated molecular weight, 932.47). ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Synthesis of $N H _ { 2 }$ -lys(Dde)- $P E G _ { 4 }$ -biotin.Fmoc-lys(Dde)- $\\mathrm { P E G } _ { 4 }$ -biotin (7.87 mg, $8 . 4 \\mu \\mathrm { m o l }$ )was taken in $20 \\%$ piperidine in DMF (vol:vol).The solution was stirred at RT for $0 . 5 \\mathrm { h }$ ,and the product was isolated by HPLC (method 4).Fractions at $1 7 \\mathrm { m i n }$ were collected. $\\mathrm { N H } _ { 2 }$ -lys(Dde) $\\mathrm { . P E G _ { 4 } }$ -biotinwas obtained at $8 3 \\%$ yield with ${ > } 9 5 \\%$ （20 HPLC purity.The high-resolution mass spectrometry (HRMS) data were as follows: HRMS(ESI): $\\mathrm { m / z } = 7 1 1 . 4 1$ ， calculated for $\\mathrm { C _ { 3 4 } H _ { 5 8 } N _ { 6 } O _ { 8 } S ( M + H ) ^ { + } }$ : 711.41. ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Synthesis of HYNIC-lys(Dde)- $\\mathsf { P E G } _ { 4 }$ -biotin.HYNIC-lys(Dde)- $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin conjugate was prepared as previously described.Briefly,a solution of $7 . 0 \\mu \\mathrm { m o l }$ of $\\mathrm { N H } _ { 2 }$ -lys(Dde)- $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin was mixed with $1 1 . 1 \\mu \\mathrm { m o l }$ of HYNIC-NHS in $1 \\mathrm { m L }$ of DMF. The $\\mathrm { \\Delta p H }$ was adjusted to $8 . 5 – 9 . 0$ using DIEA.After stirring overnight at RT, HYNIC-lys(Dde)- $\\mathrm { P E G } _ { 4 }$ -biotin was isolated by semipreparative HPLC (method 3).Fractions at $2 3 . 0 \\mathrm { m i n }$ were collected.HYNIC-lys(Dde)- $\\mathrm { . P E G _ { 4 } }$ -biotin was obtained at $57 \\%$ yield with ${ > } 9 5 \\%$ HPLC purity. The matrix-assisted laser desorption/ionization (MALDI) time-of-light(TOF) mass spectrometry(MS)data were as follows: $\\mathrm { m } / \\mathrm { z } { = } 1 0 1 4 . 5 6$ for $[ \\mathrm { M } \\mathrm { + H } ] ^ { + }$ ,1036.64 for $[ \\mathrm { M } + \\mathrm { N a } ] ^ { + }$ ,and 1052.53 for $[ \\mathrm { M } \\mathrm { + K } ] ^ { + }$ 0 $\\mathrm { \\dot { C } _ { 4 7 } H _ { 6 7 } N _ { 9 } O _ { 1 2 } S _ { 2 } }$ calculated molecular weight, 1013.44). ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Synthesis of HYNIC- $| \\forall S ( N H _ { 2 } ) \\cdot P E G _ { 4 }$ -biotin. HYNIC-lys(Dde)- $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin $\\mathrm { \\langle 4 . 1 3 m g }$ 0 $4 . 1 \\mu \\mathrm { m o l }$ )was taken in $5 \\%$ hydrazine in DMF(vol:vol).The solution was stirred at RT for $0 . 5 \\mathrm { h }$ ,and the product was isolated by HPLC (method 4).Fractions at $1 9 . 0 \\mathrm { m i n }$ were collected.HYNIC-lys $\\mathrm { ( N H } _ { 2 } )$ $\\mathrm { P E G } _ { 4 }$ -biotinwasobtained at $8 7 \\%$ yield with ${ > } 9 5 \\%$ HPLC purity. The matrix-assisted laser desorption/ionization time-of-light mass spectrometry data were as follows: $\\mathrm { m } / \\mathrm { z } = 8 5 0 . 3$ for $[ \\mathrm { M } \\mathrm { + H } ] ^ { + }$ ,872.3 for $[ \\mathrm { M } + \\mathrm { N a } ] ^ { + }$ ,888.3 for $[ \\mathrm { M } + \\mathrm { K } ] ^ { + }$ $\\mathrm { ' C } _ { 3 7 } \\mathrm { H } _ { 5 5 } \\mathrm { N } _ { 9 } \\mathrm { O } _ { 1 0 } \\mathrm { S } _ { 2 }$ ,calculated molecular weight 849.35). ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Synthesis of HYNIC-lys(Cy5.5)-biotin.A solution of $1 . 0 \\operatorname* { m g } \\left( 1 . 1 7 \\mu \\mathrm { m o l } \\right)$ of HYNIC-lys $\\left( \\mathrm { N H } _ { 2 } \\right)$ $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin was mixed with $1 . 2 \\mathrm { m g }$ $\\mathrm { \\bar { 1 } } . 5 8 \\mathrm { \\mu } \\mathrm { m o l } \\mathrm { \\mu }$ of NHS-Cy5.5 in $5 0 \\mu \\mathrm { L }$ of 0.i M $\\mathrm { N a } _ { 2 } \\mathrm { B } _ { 4 } \\mathrm { O } _ { 7 }$ buffer $( \\mathrm { p H } = 8 . 5 )$ ). After stirring overnight in the dark at RT,HYNIC-lys(Cy5.5)- $\\mathrm { P E G } _ { 4 }$ -biotin was isolated by semipreparative HPLC (method 4). Fractions at $1 8 . 6 \\mathrm { m i n }$ were collected.HYNIC-lyst $( \\mathrm { C y } 5 . 5 )$ $\\mathrm { P E G } _ { 4 }$ -biotinwasobtained at $5 2 . 1 \\%$ yield with ${ > } 9 5 \\%$ HPLC purity. Matrix-assisted laser desorption/ionization(MALDI) time-of-light (TOF) masspectrometry (MS) data were as follows: $\\mathrm { m / z } = 1 8 4 2 . 3$ for $[ \\mathrm { M } + \\mathrm { H } ] ^ { + } ( \\mathrm { C } _ { 4 7 } \\mathrm { H } _ { 6 7 } \\mathrm { N } _ { 9 } \\mathrm { O } _ { 1 2 } \\mathrm { S } _ { 2 }$ calculated molecular weight i013.44). ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "99mTc Radiolabeling and Dose Preparation.Toaclean vial were added $2 0 \\mu \\ g$ of HYNIC-lys $( \\mathrm { C y } 5 . 5 )$ ， PEG4-biotin, $3 \\mathrm { m g }$ of TPPTS and $1 0 \\mathrm { m g }$ of tricine in $1 0 0 \\mu \\mathrm { L }$ of $2 5 \\mathrm { m M }$ succinate buffer $\\mathrm { ( p H } 5 . 0 )$ . To the solution was added $1 0 0 \\mu \\mathrm { L }$ of $\\mathrm { N a ^ { 9 9 m } T c O _ { 4 } }$ solution $( { \\sim } 3 7 0 \\mathrm { M B q } )$ . The mixture was heated at $1 0 0 ^ { \\circ } \\mathrm { C }$ for $3 0 \\mathrm { m i n }$ . After heating, the vial was cooled down to room temperature for ${ \\sim } 1 0 \\mathrm { m i n }$ . A sample of the resulting solution was analyzed by radio-HPLC(Method 2)and $\\mathrm { I T L C } ^ { 2 8 , 2 9 }$ ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Doses for animal studies were prepared bydissolving the purified radiotracers in saline to yield a concentration of $1 . 8 5 \\mathrm { M B q / m L }$ for the biodistribution study and $1 8 5 . 0 \\mathrm { M B q / m L }$ for the planar imaging study. The resulting solutions were filtered with a $0 . 2 0 \\mathrm { - } \\mu \\mathrm { m }$ Millex-LG filter unit before being injected into animals. Each tumor-bearing mouse was injected with $0 . 1 \\mathrm { m L }$ of the dose solution. ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Cell Culture and Animal Model.LS180 human colon adenocarcinoma cels were obtained from American Type Culture Collection (Manassas,VA) and were cultured in MEM medium with $1 0 \\%$ fetal bovine serum (FBS) at $3 7 ^ { \\circ } \\mathrm { C }$ in a humidified atmosphere containing $5 \\%$ $\\mathrm { C O } _ { 2 }$ .Female BALB/c nude mice(4-5 weeks of age) were purchased from the Departmentof Experimental Animal,Peking University Health Science Center.Nude mice were intraperitoneally injected with $1 \\times 1 0 ^ { 6 }$ cultured LS180 cells. All of the animal experiments were approved by Peking University Health Science Center Animal Care Commitee (Institutional Animal Care and Use Committee atPeking University) and carried out in accordance with the approved guidelines. ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "Biodistribution Study.For biodistribution studies,LS180 tumor-bearing mice $( 2 0 - 2 5 \\mathrm { g } )$ were randomly divided into groups of four mice each. Mice $( \\mathrm { n } { = } 1 2 ^ { \\cdot }$ ) received a single intraperitoneal (i.p.)administration of $2 0 0 \\mu \\ g /$ mouse of avidin (in $1 0 0 \\mu \\mathrm { L }$ of saline),and the other four mice were administered with $1 0 0 \\mu \\mathrm { L }$ of saline.After four hours,each animal was injected intravenously with $1 8 5 \\mathrm { k B q }$ of $^ { 9 9 \\mathrm { m } } \\mathrm { T c }$ -HYNIC-lys(Cy5.5) $\\cdot \\mathrm { P E G } _ { 4 }$ -biotin.Animals were anesthetized with an intraperitoneal injection of sodium pentobarbital at a dose of $4 5 . 0 \\mathrm { m g / k g }$ .Mice were sacrificed by cervical dislocation at1,2,and $\\mathrm { 4 h }$ postinjection (p.i.).Blood, heart,liver,spleen,lung,kidney, stomach,intestine,bone,muscle,and tumor were harvested,weighed,and measured for radioactivity ina $\\gamma$ -counter (Wallac1470-O02; Perkin-Elmer,Finland).Organ uptake was calculatedasthe percentageoftheinjecteddose per gram of tissue $\\left( \\% \\mathrm { I D / g } \\right)$ .The biodistribution data were reported as an average plus the standard deviation (mean $\\pm$ SD) based on the results from four animals at each time point. ",
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "Dual-modality Imaging.The $\\gamma$ -imaging study was performed on female BALB/c nude mice bearing the LS180 human colon adenocarcinoma xenografts.Each tumor-bearing mouse was anesthetized with isoflurane and administered an intravenous dose of $2 0 0 \\mu \\ g$ of avidin in $1 0 0 \\mu \\mathrm { L }$ of saline or saline only.After four hours, the mice were administered an intravenous dose of $1 8 . 5 \\mathrm { M B q }$ （ $( 1 \\mathrm { m C i / 1 \\mu g } )$ of ${ } ^ { 9 9 \\mathrm { m } } \\mathrm { T c } \\mathrm { - } \\mathrm { H Y N I C - } \\mathrm { l y s } ( \\mathrm { C y } 5 . 5 ) \\mathrm { - } \\mathrm { P E G _ { 4 } }$ -biotin in $1 0 0 \\mu \\mathrm { L }$ of saline.Tumor-bearing mice were imaged by nanoSPECT/CT(Mediso Ltd. Hungary).Next, the animals were sacrificed,and optical imaging of major organs was performed using Maestro2 (Perkin Elmer). ",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "Cell Staining.The LS180 cell staining study was performed with some modifications. Briefly, $70 \\%$ to $8 5 \\%$ confluent tumor cells grown in $3 5 \\mathrm { - m m }$ MatTek glass-bottomed culture dishes were fixed using $4 \\%$ paraformaldehyde for $1 0 \\mathrm { m i n }$ . After blocking with $1 0 \\%$ FBS in PBS for $3 0 \\mathrm { m i n }$ ,the cells were incubated with avidin $( 5 \\mu \\mathrm { g } / \\mathrm { m L } )$ （204号 for $2 \\mathrm { h }$ at $3 7 ^ { \\circ } \\mathrm { C }$ The cells were then washed with PBS and stained with HYNIC- $\\mathrm { l y s } ( \\mathrm { C y } 5 . 5 ) – \\mathrm { P E G } _ { 4 }$ -biotin $( 2 \\mu \\mathrm { g } / \\mathrm { m L } )$ （204号 for $6 0 \\mathrm { { m i n } }$ . After the final wash with PBS,the cells were visualized usinga Leica TCS-NTconfocal microscope (Wetzler). ",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "Data and Statistical Analysis. The biodistribution data are reported as averages $\\pm$ standard deviation based on results from four tumor-bearing mice at each time point. Comparisons between the two biodistribution groups were performed using the t-test (GraphPad Prism 5.0,San Diego, CA).A Pvalue less than 0.O5 was considered to be statistically significant. ",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "References ",
        "text_level": 1,
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "1.vanDam,G.M.etalItraoperativetumor-specififluorescenceimagingiovriancancerbfolatereceptor-alhatargetingfrst in-human results.Nat Med 17,1315-1319,doi: 10.1038/nm.2472 (2011). 2.Kerewee,S.etalImageguidedsurgeryineadandneckcancer:currentpracticeandfuturedirectionsofopticalimaging.Head Neck 34,120-126,doi: i0.1002/hed.21625 (2012). 3.Tanaka,Eoi,H..uj,wedi,.G.&angioi,JVagudedoncologicugersingivisiblelge pre-clinicaldevelopmentforsentinellymphnode mapping.AnnSurgOncol.AnSurgOncol13,1671-681,doi:10.1245/s10434- 006-9194-6 (2006). 4.Frangioni,J.V.In vivo near-infrared fluorescence imaging.CurrOpin Chem Biol7,626-634 (2003). 5.Kuil,J,Vedrs,.H.&n,uliodaloagegptidcioadithddt label.Bioconjug Chem 21,1709-1719,doi:10.1021/bc100276j (2010).   \n6.Uppal,J.K.etllogicalevauationfvidi-basedtumorpretargetingthOTA-iazoleBiotinconstructediasatile $\\mathtt { C u ( I ) }$ （204号 catalyzed click chemistry.JDrug Target19,418-426,doi:10.3109/1061186x.2010.504269 (2011).   \n7.Goldenbeg,D..etlPretargeedoleculariagigadraiommunotherpyeranostics2,52-54di:/5 (2012).   \n8.Wang,L.et al.Improving tumor-targeting capability and pharmacokinetics of $( 9 9 \\mathrm { m } )$ Tc-labeled cyclic RGD dimers with PEG(4) linkers.Mol Pharm6,231-245,doi:i0.1021/mp800i50r(2009).   \n9.Yao,Z.et al.Avidin targetingofintraperitoneal tumor xenografts.JNatl Cancer Inst90,25-29 (1998).   \n10.Reardan,D.T.et al.Antibodies against metal chelates.Nature 316,265-268 (1985).   \n11.Hnatowich,D.JVi&usoki,vestigatisofvdinadtinforagngalicatis.Jucled293 (1987).   \n12.Marysael,T.etal.Pretargetingofecrotictumorswithbotiylatedhypericinusing3-lbeledavdin:evaluationoftwostep strategy.Invest New Drugs 30,2132-2140,doi: 10.1007/s10637-011-9778-2 (2012).   \n13.Sharkey,R.M.etal.Signalamplificationinmolecularimagingbypretargetingamultivalent,bspecifantibody.NatMed1, 1250-1255,doi: 10.1038/nm1322 (2005).   \n14.Sharkey,R.M.etlMetastatichumancoloniccarcinoma: molecularimaging withpretargetedSECTandPETinaouseodel. Radiology 246,497-507,doi:10.1148/radiol.2462070229 (2008).   \n15.Schoffelen,R.etlPretargetedimmuno-ositonsiotomogaphyimagingofcarcinoembryonicanigen-expressngumors withabispecificantibodyanda68Ga-and18F-labeledhaptenpeptideinmicewithhuman tumor xenografts.MolCancerTher9, 1019-1027,doi:10.1158/1535-7163.mct-09-0862 (2010).   \n16.Lewis,M.R.etal.Invivoevaluationofpretargeted64Cufortumorimagingandtherapy.JNuclMed44,284-292 (2003).   \n17.Sharkey,R.M.etal.ispeicntibodypretargetigofadionuclidesforimunosingle-photoneisiocomputedoogaphy andimmunopositronemisiontomographymolecularimaging:anupdate.ClinCancerRes13,5577s-558s,doi:10.1158/1078-0432. ccr-07-1087 (2007).   \n18.Liu,G.etal.Pretargetings.recttargeingofhumanetalo5isletcelssubutaneouslyimplantedinceusiganantiman islet cell antibody.Nucl Med Biol 39,645-651,doi: 10.1016/j.nucmedbio.2011.12.001(20i2).   \n19.Mamede,M.etal.Radiolabelingofavidinwithveryhigh specificactivityforinternalradiationtherapyofintraperitoneally disseminated tumors. Clin Cancer Res 9,3756-3762 (2003).   \n20.Ip,Y.T.,DiasFloM.A.&ChanJ.K.Nuclearinclusionsandpseudoiclusions:friendsorfesofthesurgicalpathologist?IntJ Surg Pathol 18,465-481,doi: 10.1177/1066896910385342 (2010).   \n21.Nakatani,Y.etaloti-rhptcallearucleexpresestrogenrecetorbeta:tumorswithmorlesaydevelore influence of estrogen and aberrant beta-catenin expression.Hum Pathol 35,869-874(2004).   \n22.Bhushan,K.R.etal.Detectionofbreastcancermicrocalcifcationsusingadual-modalitySECT/NIRfuorescentprobe.JAmCem Soc 130,17648-17649,doi: 10.1021/ja807099s (2008).   \n23.Townsen,D.WDuaodalitymaging:mbingaatomyandfunction.JNuclMd49,93-95,doi:196/jumed081 (2008).   \n24.Weissleder,R.& Mahmood, U.Molecular imaging.Radiology 219,316-333 (2001).   \n25.NtziachristosV,rer,C.&Wsderuoresenceagingitharfraedlghttologicaldacetaabe in vivo molecular imaging.Eur Radiol13,195-208,doi:10.1007/s00330-002-1524-x (2003).   \n26.Klausen,TLetal.RadiationdosetostafinvolvedinsntielnodeoperationsforbreastcancerClnPysiolFunctImaging5, 196-202,doi: 10.1111/j.1475-097X.2005.00611.x (2005).   \n27.Waddington,W.A.etal.Radationsafetyofthesentiellymphodetechniqueinbreastcancer.EurJNuclMedMolImaging27, 377-391 (2000).   \n28.Shi,J.etal.99mTc-lbeledbombesin(7-4)NH2ithfavorablepropertiesforSECTimagingofcoloncancerBoconjugChem19,   \n1170-1178,doi: 10.1021/bc700471z (2008).   \n29.JiaB.etal.9mTc-labeledcycicGDfKdimer:initialevaationforECTimagingofliomainteginlphavbeta3exrssion. Bioconjug Chem17,1069-1076,doi:10.1021/bc060055b (2006). ",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "Acknowledgements ",
        "text_level": 1,
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "This research was supported by $^ { \\mathfrak { e } } 9 7 3 ^ { \\mathfrak { n } }$ projects (2013CB733802 and 2011CB707703),National Natural Science Foundation of China (NSFC)projects (81125011,81222019,81471712,81420108019,81371614,81321003, 81427802 and 81201127),grants from the Ministry of Science and Technology of China (2011YQ030114, 2012ZX09102301-018,and 2012BAK25B03-16),grants from the Ministry of Education of China (31300 and BMU20110263),grants from Beijing Natural Science Foundation (7142086,7132131and 7132123),a grant from the Beijing Ministry of Science and Technology (Z14110000214004),and a grant from Beijing Nova Program (Z121107002512010). ",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "Author Contributions ",
        "text_level": 1,
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "C.D.preparedFigures1\\~4,interpreteddataand wrote the main manuscripttext.S.Y.prepared the product (scheme1 and supplementary figures) and the quality control was carried out by L.Z. (supplementary figures). B.J.,FW. and Z.L.finished the manuscript editing.JS.and H.Z.contributed a lot on radiolabeling and animal models, respectively.All authors reviewed the manuscript. ",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "Additional Information ",
        "text_level": 1,
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "Supplementary information accompanies this paper at http://www.nature.com/srep ",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "Competing financial interests: The authors declare no competing financial interests. ",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "How to cite this article: Dong, C.et al. SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System.Sci. Rep.6,18905; doi: 10.1038/srep18905 (2016). ",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "This work is licensed undera Creative Commons Attribution 4.0 International License.The images or other third party materialin this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material.To viewa copy of this license,visit http://creativecommons.org/licenses/by/4.0/ ",
        "page_idx": 8
    }
]